{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:28:35Z","timestamp":1794540515451,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2017-83267-C2-1-R"],"award-info":[{"award-number":["SAF2017-83267-C2-1-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41591-020-0856-x","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T13:10:18Z","timestamp":1589375418000},"page":"688-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":527,"title":["Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4833","authenticated-orcid":false,"given":"Kurt A.","family":"Schalper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4101-3185","authenticated-orcid":false,"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Pang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-5768","authenticated-orcid":false,"given":"Alice M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Baxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimple","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Baradet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata","family":"Nagineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Gianino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-9607","authenticated-orcid":false,"given":"Hongyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Perez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"856_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"856_CR2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133\u2013150 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"856_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"856_CR4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1158\/1078-0432.CCR-16-0169","volume":"22","author":"KA Schalper","year":"2016","unstructured":"Schalper, K. A., Kaftan, E. & Herbst, R. S. Predictive biomarkers for PD-1 axis therapies: the hidden treasure or a call for research. Clin. Cancer Res. 22, 2102\u20132104 (2016).","journal-title":"Clin. Cancer Res."},{"key":"856_CR5","doi-asserted-by":"crossref","unstructured":"Moore, B. B. et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 154, 1503\u20131512 (1999).","DOI":"10.1016\/S0002-9440(10)65404-1"},{"key":"856_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fimmu.2015.00285","volume":"6","author":"M Baggiolini","year":"2015","unstructured":"Baggiolini, M. CXCL8 \u2014 the first chemokine. Front. Immunol. 6, 285 (2015).","journal-title":"Front. Immunol."},{"key":"856_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI114265","volume":"84","author":"M Baggiolini","year":"1989","unstructured":"Baggiolini, M., Walz, A. & Kunkel, S. L. Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84, 1045\u20131049 (1989).","journal-title":"J. Clin. Invest."},{"key":"856_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/vaccines4030022","volume":"4","author":"JM David","year":"2016","unstructured":"David, J. M., Dominguez, C., Hamilton, D. H. & Palena, C. The IL-8\/IL-8R axis: a double agent in tumor immune resistance. Vaccines 4, 22 (2016).","journal-title":"Vaccines"},{"key":"856_CR9","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro, C. et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin. Cancer Res. 22, 3924\u20133936 (2016).","journal-title":"Clin. Cancer Res."},{"key":"856_CR10","doi-asserted-by":"crossref","unstructured":"Sanmamed, M. F. et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann. Oncol. 28, 1988\u20131995 (2017).","DOI":"10.1093\/annonc\/mdx190"},{"key":"856_CR11","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, dju124 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"856_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16, 431\u2013446 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"856_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2013.06.010","volume":"59","author":"T Kapanadze","year":"2013","unstructured":"Kapanadze, T. et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 59, 1007\u20131013 (2013).","journal-title":"J. Hepatol."},{"key":"856_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253\u2013268 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"856_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","volume":"42","author":"JA Wargo","year":"2015","unstructured":"Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S. & Sullivan, R. J. Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin. Oncol. 42, 601\u2013616 (2015).","journal-title":"Semin. Oncol."},{"key":"856_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","volume":"7","author":"M Bilusic","year":"2019","unstructured":"Bilusic, M. et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J. Immunother. Cancer 7, 240 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"856_CR17","doi-asserted-by":"publisher","first-page":"15721","DOI":"10.18632\/oncotarget.24595","volume":"9","author":"S Conroy","year":"2018","unstructured":"Conroy, S., Kruyt, F. A. E., Wagemakers, M., Bhat, K. P. L. & den Dunnen, W. F. A. IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. Oncotarget 9, 15721\u201315731 (2018).","journal-title":"Oncotarget"},{"key":"856_CR18","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"856_CR19","doi-asserted-by":"publisher","first-page":"e0179726","DOI":"10.1371\/journal.pone.0179726","volume":"12","author":"NO Siemers","year":"2017","unstructured":"Siemers, N. O. et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS ONE 12, e0179726 (2017).","journal-title":"PLoS ONE"},{"key":"856_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"856_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"856_CR22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"856_CR23","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"856_CR24","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2018.36.15_suppl.3025","volume":"36","author":"M Carleton","year":"2018","unstructured":"Carleton, M. et al. Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy. J. Clin. Oncol. 36, 3025 (2018).","journal-title":"J. Clin. Oncol."},{"key":"856_CR25","doi-asserted-by":"crossref","first-page":"CT073","DOI":"10.1158\/1538-7445.AM2017-CT073","volume":"77","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038. Cancer Res. 77, CT073 (2017).","journal-title":"Cancer Res."},{"key":"856_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949 (2017).","journal-title":"Cell"},{"key":"856_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 17, 943\u2013955 (2016).","journal-title":"Lancet Oncol."},{"key":"856_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 56, 337\u2013344 (2000).","journal-title":"Biometrics."},{"key":"856_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"The Cancer Genome Atlas Research Network et al.","year":"2013","unstructured":"The Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"856_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"856_CR31","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-17-2542","volume":"24","author":"F Villarroel-Espindola","year":"2018","unstructured":"Villarroel-Espindola, F. et al. Spatially resolved and quantitative analysis of VISTA\/PD-1H as a novel immunotherapy target in human non\u2013small cell lung cancer. Clin. Cancer Res. 24, 1562\u20131573 (2018).","journal-title":"Clin. Cancer Res."},{"key":"856_CR32","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","volume":"25","author":"I Datar","year":"2019","unstructured":"Datar, I. et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non\u2013small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin. Cancer Res. 25, 4663\u20134673 (2019).","journal-title":"Clin. Cancer Res."},{"key":"856_CR33","doi-asserted-by":"publisher","first-page":"dju435","DOI":"10.1093\/jnci\/dju435","volume":"107","author":"KA Schalper","year":"2015","unstructured":"Schalper, K. A. et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J. Natl Cancer Inst. 107, dju435 (2015).","journal-title":"J. Natl Cancer Inst."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0856-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0856-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0856-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:02:46Z","timestamp":1684605766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-0856-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-0856-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737946868.793579479","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"27 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M. reports receiving commercial research grants from Bristol-Myers Squibb, Bioncotech, Alligator, AstraZeneca and Roche; has received speakers bureau honoraria from MSD; and is a consultant\/advisory board member for Bristol-Myers Squibb, Roche, Genmab, F-Star, Bioncotech, Bayer, Numab, Alligator, Boehringer Ingelheim and AstraZeneca. K.A.S. reports receiving research funding from Genoptix\/Navigate (Novartis), Vasculox\/Tioma, Tesaro, Moderna Therapeutics, Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca and Eli Lilly; has received consultant\/advisory board fees from Celgene, Moderna Therapeutics, Shattuck Labs, Pierre-Fabre, AbbVie, AstraZeneca, EMD Serono, Ono Pharmaceuticals, Clinica Alemana de Santiago, Dynamo Therapeutics, Torque Therapeutics, Agenus and Takeda; and has received speaker honoraria and\/or travel support for meetings from Takeda, Merck, Bristol-Myers Squibb, Fluidigm, Peerview, Biotrac, Cambridge Healthtech Institute, Shattuck Labs and Genentech. J.L.P.-G. reports grants, personal fees and nonfinancial support from Roche, Bristol-Myers Squibb and MSD; and reports grants and personal fees from Ipsen and Eisai, and grants from Incyte and Janssen. M.C., M.Z., S.-P.H., T.C. and Y.F. have a patent (\u2018Combination Therapy with Anti-IL-8 Antibodies and Anti-PD-1 Antibodies for Treating Cancer\u2019, publication number WO 2019140150). T.P.R. is a co-inventor in a provisional patent application (application number 62\/650047) regarding the use of anti-IL-8 and anti-PD1 for the treatment of cancer. M.C., M.Z., T.C., Y.F., S.-P.H., A.M.W, V.B, D.P., T.B., D.L., T.P.R., P.P., J.G. and H.Z. are current or former employees of Bristol-Myers Squibb, which is developing anti-IL-8 (NCT03400332). T.P.R., A.M.W., D.L. and S.-P.H. own stock in Bristol-Myers Squibb. None of the remaining authors have relevant conflicts of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}